[HTML][HTML] Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported …

E Vilar-Gomez, SJ Athinarayanan, RN Adams… - BMJ open, 2019 - bmjopen.bmj.com
BMJ open, 2019bmjopen.bmj.com
Objective One year of comprehensive continuous care intervention (CCI) through nutritional
ketosis improves glycosylated haemoglobin (HbA1c), body weight and liver enzymes among
patients with type 2 diabetes (T2D). Here, we report the effect of the CCI on surrogate scores
of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. Methods This was a non-
randomised longitudinal study, including adults with T2D who were self-enrolled to the CCI
(n= 262) or to receive usual care (UC, n= 87) during 1 year. An NAFLD liver fat score (N …
Objective
One year of comprehensive continuous care intervention (CCI) through nutritional ketosis improves glycosylated haemoglobin(HbA1c), body weight and liver enzymes among patients with type 2 diabetes (T2D). Here, we report the effect of the CCI on surrogate scores of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis.
Methods
This was a non-randomised longitudinal study, including adults with T2D who were self-enrolled to the CCI (n=262) or to receive usual care (UC, n=87) during 1 year. An NAFLD liver fat score (N-LFS) >−0.640 defined the presence of fatty liver. An NAFLD fibrosis score (NFS) of >0.675 identified subjects with advanced fibrosis. Changes in N-LFS and NFS at 1 year were the main endpoints.
Results
At baseline, NAFLD was present in 95% of patients in the CCI and 90% of patients in the UC. At 1 year, weight loss of ≥5% was achieved in 79% of patients in the CCI versus 19% of patients in UC (p<0.001). N-LFS mean score was reduced in the CCI group (−1.95±0.22, p<0.001), whereas it was not changed in the UC (0.47±0.41, p=0.26) (CCI vs UC, p<0.001). NFS was reduced in the CCI group (−0.65±0.06, p<0.001) compared with UC (0.26±0.11, p=0.02) (p<0.001 between two groups). In the CCI group, the percentage of individuals with a low probability of advanced fibrosis increased from 18% at baseline to 33% at 1 year (p<0.001).
Conclusions
One year of a digitally supported CCI significantly improved surrogates of NAFLD and advanced fibrosis in patients with T2D.
Trial registration number
NCT02519309; Results.
bmjopen.bmj.com
以上显示的是最相近的搜索结果。 查看全部搜索结果

Google学术搜索按钮

example.edu/paper.pdf
搜索
获取 PDF 文件
引用
References